MARKET

JNJ

JNJ

Johnson & Johnson
NYSE
144.77
+0.32
+0.22%
Pre Market: 144.96 +0.19 +0.13% 05:34 04/18 EDT
OPEN
145.00
PREV CLOSE
144.45
HIGH
145.41
LOW
143.54
VOLUME
154
TURNOVER
0
52 WEEK HIGH
175.97
52 WEEK LOW
142.71
MARKET CAP
348.86B
P/E (TTM)
10.54
1D
5D
1M
3M
1Y
5Y
Hold Rating on Johnson & Johnson Amidst Growth, Competition, and Legal Challenges
TipRanks · 5h ago
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Johnson & Johnson (JNJ) and Lantheus (LNTH)
Savara, Johnson & Johnson and Lantheus are 3 of the top 3 Healthcare stocks recommended by analysts. Savara has an analyst consensus of Strong Buy, with a price target of $8.80. 3 analysts have reiterated a Buy rating on Savara.
TipRanks · 7h ago
Scotiabank upgrades Legend Biotech to sector outperform
Seeking Alpha · 15h ago
Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future
Johnson & Johnson reported first-quarter adjusted EPS of $2.71, up 12.4% year over year. The pharma giant reported sales of $21.38 billion. Cantor Fitzgerald remains positive on Johnson & Johnson’s stock. The analyst says the market is undervaluing the potential sales of new drugs.
Benzinga · 16h ago
JNJ's Carvykti Sales Disappointed in 1Q -- Market Talk
Sales of Johnson & Johnson's Carvykti were disappointing in the first quarter, BofA says. The oncology drug's outlook has caused investor debate, the bank says. But investor sentiment can improve on better-than-expected quarterly performance and pipeline readouts, it says.
Dow Jones · 16h ago
Johnson & Johnson Analysts Cut Their Forecasts After Q1 Results
Johnson & Johnson reported better-than-expected first-quarter earnings on Tuesday. The company posted adjusted EPS of $2.71, up 12.4% year over year. The pharma giant also raised its quarterly dividend by 4.2%. Johnson & Johnson shares fell 0.2% to trade at $144.12 on Wednesday.
Benzinga · 17h ago
Johnson & Johnson Price Target Cut to $175.00/Share From $181.00 by RBC Capital
Dow Jones · 18h ago
Johnson & Johnson Is Maintained at Outperform by RBC Capital
Dow Jones · 18h ago
More
About JNJ
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, and vision fields. These products are distributed to wholesalers, hospitals, and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.

Webull offers Johnson & Johnson stock information, including NYSE: JNJ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JNJ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JNJ stock methods without spending real money on the virtual paper trading platform.